Miranda Jayne Toledano - 16 Jul 2025 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ENTX
Reported as of: 16 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jul 2025, 16:37:05 UTC
Prior SEC filing: 07 Jul 2025
Next SEC filing: 07 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Dana Yaacov-Garbeli, Attorney-in-Fact

Key filing fact

Miranda Jayne Toledano filed Form 4 for Entera Bio Ltd. (ENTX) on 18 Jul 2025.

Key facts

This page summarizes Miranda Jayne Toledano's Form 4 filing for Entera Bio Ltd. (ENTX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Jul 2025, 16:37.

Change

Previous filing in this sequence was filed on 07 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001686530 Primary reporting owner

Toledano Miranda Jayne

Relationship: Chief Executive Officer, Director
Address: KIRYAT HADASSAH,, MINRAV BUILDING, 5TH FLOOR, JERUSALEM, ISRAEL
Signature: /s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Signature date: 18 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ENTX transaction

Ordinary Shares, par value NIS 0.0000769 per share

Award

Transaction value: $0
Shares: +136,842
Change %: +58%
Price: $0.000000
Shares after: 371,715
Date: 16 Jul 2025
Ownership: Direct
Footnotes: F1

ENTX transaction

Ordinary Shares, par value NIS 0.0000769 per share

Award

Transaction value: $0
Shares: +43,860
Change %: +12%
Price: $0.000000
Shares after: 415,575
Date: 16 Jul 2025
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ENTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +500,000
Change %
Price: $0.000000
Shares after: 500,000
Date: 16 Jul 2025
Ownership: Direct
Underlying class: Ordinary Shares, par value NIS 0.0000769 per share
Underlying amount: 500,000
Exercise price: $2.28
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. This grant was awarded to the Reporting Person in lieu of the Reporting Person's 2024 annual cash bonus. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 28, 2025.

Footnote F2

Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. This grant was awarded to the Reporting Person in lieu of $100,000 the Reporting Person is entitled to under the Reporting Person's base salary for 2025. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 1, 2025.

Footnote F3

This grant of options was approved by the Board on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. The options vest over a three-year period that commenced on April 28, 2025, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.